Detalhe da pesquisa
1.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084760
2.
Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma.
Br J Clin Pharmacol
; 89(5): 1640-1655, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36484341
3.
Current Health State Affected Patient Preferences More Than Disease Status: A Discrete Choice Experiment in Multiple Myeloma.
Value Health
; 26(6): 909-917, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36738785
4.
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.
J Oncol Pharm Pract
; 29(5): 1172-1177, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36067063
5.
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial.
Am J Hematol
; 97(4): 481-490, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35089607
6.
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(6): 801-812, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34087126
7.
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
Br J Haematol
; 194(1): 132-139, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33822368
8.
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Br J Haematol
; 192(5): 869-878, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33216361
9.
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
N Engl J Med
; 378(6): 518-528, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29231133
10.
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.
Blood
; 131(9): 995-999, 2018 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29305553
11.
Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial.
Ann Hematol
; 98(12): 2805-2814, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31620815
12.
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX.
Blood Adv
; 8(2): 388-398, 2024 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048391
13.
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.
J Clin Oncol
; 41(8): 1600-1609, 2023 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36413710
14.
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.
Lancet Haematol
; 10(10): e813-e824, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37793772
15.
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.
J Clin Oncol
; 41(8): 1590-1599, 2023 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36599114
16.
Patient Perceptions Regarding Multiple Myeloma and Its Treatment: Qualitative Evidence from Interviews with Patients in the United Kingdom, France, and Germany.
Patient
; 14(5): 613-623, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33686594
17.
Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 21(1): 46-54.e4, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33485428
18.
Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients.
J Clin Pharmacol
; 61(5): 614-627, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33145788
19.
Allelic variation at the A218C tryptophan hydroxylase polymorphism influences agitation and aggression in Alzheimer's disease.
Neurosci Lett
; 363(3): 199-202, 2004 Jun 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-15182943